Janux Therapeutics Inc Forecast, price target & analysts
Janux Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Janux Therapeutics Inc Classifications & Recommendation:
Janux Therapeutics Inc Price Target
| Target Price | $83.92 |
| Price | $28.80 |
| Potential |
191.38%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Janux Therapeutics Inc 2026 .
The average Janux Therapeutics Inc target price is $83.92.
This is
191.38%
register free of charge
$200.00
594.44%
register free of charge
$25.00
13.19%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Janux Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Janux Therapeutics Inc stock has an average upside potential 2026 of
191.38%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 10.59 | 2.42 |
| 31.06% | 77.18% | |
| EBITDA Margin | -913.98% | -5,395.31% |
| 3.98% | 490.31% | |
| Net Margin | -713.85% | -4,021.51% |
| 26.01% | 463.35% |
12 Analysts have issued a sales forecast Janux Therapeutics Inc 2025 . The average Janux Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Janux Therapeutics Inc EBITDA forecast 2025. The average Janux Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Janux Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Janux Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.28 | -1.65 |
| 3.03% | 28.91% | |
| P/E | negative | |
| EV/Sales | 289.69 |
9 Analysts have issued a Janux Therapeutics Inc forecast for earnings per share. The average Janux Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Janux Therapeutics Inc...
Current Janux Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Dec 04 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 03 2024 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Dec 03 2024 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Dec 04 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 03 2024 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Dec 03 2024 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 03 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
